Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report
Abstract Background Nintedanib is a tyrosine kinase inhibitor that efficiently slows the progression of idiopathic pulmonary fibrosis (IPF) and has an acceptable tolerability profile. In contrast, immune checkpoint inhibitors (ICIs) such as programmed death 1 and programmed death ligand 1 inhibitors...
Main Authors: | Hideaki Yamakawa, Tomohiro Oba, Hiroki Ohta, Yuta Tsukahara, Gen Kida, Emiri Tsumiyama, Tomotaka Nishizawa, Rie Kawabe, Shintaro Sato, Keiichi Akasaka, Masako Amano, Kazuyoshi Kuwano, Hidekazu Matsushima |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-08-01
|
Series: | BMC Pulmonary Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12890-019-0920-9 |
Similar Items
-
Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer
by: Xiao-Hong Xie, et al.
Published: (2021-06-01) -
Focus on Nintedanib in NSCLC and other tumors
by: Anna Manzo, et al.
Published: (2016-12-01) -
Current Diagnosis and Management of Hypersensitivity Pneumonitis
by: Paolo Maria Leone, M.D., et al.
Published: (2020-04-01) -
Profile of nintedanib in the treatment of solid tumors: the evidence to date
by: Awasthi N, et al.
Published: (2015-12-01) -
Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity
by: Seidai Sato, et al.
Published: (2017-09-01)